Science and Technology Science and Technology
Tue, May 13, 2025
[ Yesterday Morning ] - BBC
Hibernian v Celtic
[ Yesterday Morning ] - BBC
Motherwell v Glasgow City
[ Yesterday Morning ] - TMJ4
America's Mental Health Struggles
[ Yesterday Morning ] - Chowhound
12 Fast Food Burgers, Ranked
[ Yesterday Morning ] - WSAZ
Food Fair's Anniversary Sale
[ Yesterday Morning ] - Forbes
Is Your Data Fit For Purpose?

Microbix & Aurevia Introduce Novel EQA Scheme


Published on 2025-05-13 07:42:13 -
  Print publication without navigation

  • MISSISSAUGA, Ontario and HELSINKI, Finland, May 13, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix
  • ), a life sciences innovator, manufacturer, and exporter, and Aurevia Oy via

Microbix Biosystems Inc. and Aurelia Bioscience Ltd. have launched a novel External Quality Assessment (EQA) scheme for point-of-care (POC) infectious disease tests, specifically targeting the growing market for rapid diagnostic tests (RDTs). This new EQA program, named REDx® QAP, is designed to enhance the quality assurance of POC tests for infectious diseases such as HIV, malaria, and syphilis, which are crucial for global health initiatives. The scheme utilizes Microbix's QAPs™ (Quality Assessment Products) and Aurelia's REDx® platform to provide a comprehensive quality control solution that can be used in resource-limited settings. The collaboration aims to improve the reliability and accuracy of POC testing, thereby supporting better patient outcomes and public health management worldwide.

Read the Full Toronto Star Article at:
[ https://www.thestar.com/globenewswire/microbix-aurevia-introduce-novel-eqa-scheme/article_499b73d0-1026-59a5-b8c1-62f7601a5345.html ]